The images showed a significant increase in the number of cells undergoing apoptosis after transduction with ABL sgRNA_2 (21.3%±4.65, apoptosis cell percentage), compared to that of SC (2.1% ± 1.2, apoptosis cell percentage)-transduced CML cells (Figure 5M, p < 0.05), indicating that the ABL-targeted CRISPR/Cas9 virus can be used an effective gene therapy strategy for clinical CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.